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Aspirin is one of the most frequently used and cheapest drugs in medicine. It belongs to 
the non-steroidal anti-inflammatory drugs with a wide range of pharmacological activities, 
including analgesic, antipyretic, and antiplatelet properties. Currently, it is accepted to 
prescribe a low dose of aspirin to pregnant women who are at high risk of preeclampsia 
(PE) because it reduces the onset of this complication. Another pregnancy alteration in 
which a low dose of aspirin is recommended is the obstetric antiphospholipid syndrome 
(APS). The most recognized mechanism of action of aspirin is to inhibit the synthesis of 
prostaglandins but this by itself does not explain the repertoire of anti-inflammatory effects 
of aspirin. Later, another mechanism was described: the induction of the production 
of aspirin-triggered lipoxins (ATLs) from arachidonic acid by acetylation of the enzyme 
cyclooxygenase-2. The availability of a stable analog of ATL has stimulated investigations 
on the use of this analog and it has been found that, similar to endogenously produced 
lipoxins, ATL resolves inflammation and acts as antioxidant and immunomodulator. If we 
consider that in PE and in the obstetric APS, there is an underlying inflammatory process, 
aspirin might be used based on the induction of ATL. The objective of this review is to 
revisit the old and new mechanisms of action of aspirin. In particular, it intends to show 
other potential uses of this drug to prevent certain pregnancy complications in the light 
of its ability to induce anti-inflammatory and pro-resolving lipid-derived mediators.
Keywords: anti-inflammatory, aspirin-triggered lipoxins, pro-resolving lipid-derived mediators, obstetric 
antiphospholipid syndrome, preeclampsia, pregnancy complications
inTRODUCTiOn
Aspirin is the trade name for acetylsalicylic acid coined by the Bayer laboratories. In many countries, 
it remains a registered trademark of this company, whereas in others aspirin has become the generic 
name of this substance.
Aspirin in low doses is the single most cost-effective medicine for the prevention of secondary 
events of thrombosis. Furthermore, low doses of aspirin (LDA) are widely used in the prevention 
of diverse alterations of gestation such as preeclampsia (PE) and the obstetric antiphospholipid 
syndrome (APS). Although controversy persists concerning the real efficiency and empirical use of 
this compound, its prescription is very common in high-risk pregnancies; moreover, its cost is low 
and it is relatively safe and easily accessible to all (1–7).
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As a part of the inflammatory response to an injury, the 
immune system develops mechanisms of control to this response, 
through the production of pro-resolving lipid mediators includ-
ing lipoxins, resolvins, protectins, and maresins. These mediators 
are produced from arachidonic acid (AA) or from omega-3 
polyunsaturated fatty acids (PUFAs), through different molecu-
lar mechanisms but that imply transcellular biosynthesis with 
the participation of different enzymes (8). Interestingly, aspirin 
induces the production of some pro-resolving lipid-derived 
mediators very similar to the ones produced endogenously that 
bind to the same receptor, conferring to aspirin some special 
properties in the resolution of inflammation (9), in addition to its 
already known pharmacological effects as analgesic, antipyretic, 
and antiplatelet drug.
This review aims to revisit the old and new mechanisms of 
aspirin’s actions and particularly show other possible effects in 
some complications of pregnancy in which aspirin has been used 
in an empirical and controversial way.
A QUiCK GLAnCe ASPiRin-TRiGGeReD 
(AT) THe HiSTORY OF ASPiRin 
DiSCOveRY
Aspirin is one of the oldest drugs in use, and it is a very repre-
sentative example of how natural products can be optimized with 
mild chemical manipulations; its use dates back to 1,500 years 
B.C., when the Egyptians used crude infusions of myrtle bark for 
rheumatism and back pain. A thousand years later, Hippocrates 
prescribed bark and leaves of the willow to relieve fever and 
pain. In 1763, the Reverend Stone reported a successful treat-
ment of 50 patients in febrile states with willow extract. In 1828, 
Buchner purified salicin and proposed it as the main component 
with antipyretic activity of this extract. In 1838, Piria success-
fully synthesized salicylic acid from salicin. In 1897, Hoffman 
achieved acetylsalicylic acid as a chemically pure and stable 
compound; in 1899, its therapeutic properties as an analgesic 
and anti-inflammatory compound were described and, in 1900, 
it was introduced into the market in the form of aspirin tablets 
(10, 11).
For many years, aspirin was widely used as household medicine 
for the treatment of fever, pain, and inflammation even though 
its mechanism of action was unknown. It was not until 1971 that 
the Vane showed that aspirin suppressed the production of some 
eicosanoids derived from AA such as prostaglandins (12). Later 
studies demonstrated that the acetylation of platelet cyclooxy-
genase (COX) by aspirin inhibits thromboxane formation and 
explains its antithrombotic effects (13).
As of 1979, reports of different actions of aspirin have been 
flourishing and include its use in the prevention of colon cancer 
(14), cardiovascular diseases such as myocardial infarction, 
strokes, and atherothrombotic events (15, 16), as well as the report 
that regular intake of aspirin during pregnancy reduces the risk 
of PE (17). One of the discoveries that interests us in the context 
of this review is the detection in 1989 by Claria and Serhan, of 
the generation of aspirin-triggered lipoxins (ATLs) from AA, by 
the interaction of acetylated COX-2 with the 5-lipoxygenase of 
white cells (18).
MeCHAniSMS OF ACTiOn OF ASPiRin
Aspirin is a prototype of non-steroidal anti-inflammatory drugs 
(NSAIDs), and member of the family of salicylates that have in 
common salicylic acid as the active agent. Salicylic acid is com-
posed of a benzene ring and two radicals, one hydroxyl and one 
carboxyl. In the acetylsalicylic acid or aspirin, the hydroxyl group 
salicylate is transformed into an acetyl group by esterification. 
The pharmacological properties of aspirin are similar to those of 
salicylates, but also to the biological actions attributed to salicy-
late itself, and it has other independent effects due to its reactive 
acetate group (11). Both components, salicylate and acetate 
groups, are biologically active and act independently of each other 
at different sites. A summary of the pharmacological actions of 
these components of aspirin are summarized in Figure 1 (18–29).
LDA (e.g., 75–100  mg/day) are sufficient to irreversibly 
acetylate serine 530 of COX-1, inhibiting platelet generation 
of thromboxane-A2, resulting in an antithrombotic effect. 
Intermediate doses of aspirin (650 mg to 4 g/day) inhibit COX-1 
and COX-2 (30). Additionally, aspirin can induce the production 
of ATL (18). This lipid mediator exerts its actions by binding to a 
G-protein-coupled receptor, named ALXR (9). A simple scheme 
of the metabolic pathways of AA is shown in Figure 2.
USe OF ASPiRin in PRevenTiOn OF Pe
Preeclampsia is a multisystem disorder defined by persistent 
hypertension during pregnancy or postpartum period that may 
be associated with proteinuria, thrombocytopenia, impaired 
liver function, progressive renal insufficiency, pulmonary edema, 
or cerebral disturbances (31). It is generally accepted that PE 
originates from the placenta, since poor trophoblast invasion 
and remodeling of spiral arteries occur, leading to reduced 
utero-placental arterial flow and episodes of hypoxia/reperfusion 
(32). These abnormalities in the perfusion of placenta generate 
reactive oxygen species that, after a while, result in the release 
of cytokines, lipid peroxides, and syncytiotrophoblast microf-
ragments from the placenta into the maternal circulation (33). 
Hence, in PE, the increased inflammation, oxidative stress, and 
endothelial dysfunction are key pathogenic features (34).
Since 1979, when the utility of aspirin intake in pregnancy 
was reported to prevent PE (17), many reports with controversial 
results on the efficiency of this drug were reported: two multi-
center studies found a slight benefit of aspirin in preventing PE 
(35, 36). Other randomized placebo-controlled trials suggest that 
LDA did not reduce the rate of PE [relative risk (RR), 0.7, 95% 
confidence interval (CI), 0.3–1.7] (37). On the other hand of the 
controversy, other reports in the literature showed results in favor 
of the beneficial effects of LDA to prevent PE: in a systematic 
review of the literature of 46 trials involving 32,891 patients, a 
moderate benefit of aspirin was found in preventing PE; LDA 
reduced the risk of PE by 17% (RR, 0.83, 95% CI, 0.77–0.89). 
These results were statistically significant independent of whether 
patients had moderate or high risk of PE, or whether they were 
included in a placebo-controlled trial (1). In a recent meta-
analysis, it was shown that LDA used before the 16th week of 
pregnancy reduces the risk of PE (RR, 0.57; 95% CI, 0.43–0.75; 
FiGURe 1 | Pharmacological and biological actions of aspirin by its salicylate and reactive acetyl group.
FiGURe 2 | Synthesis of pro-inflammatory and pro-resolving lipid mediators from arachidonic acid (AA). By the action of cyclooxygenases-1 and -2, the 
prostanoids prostacyclins, prostaglandins and thromboxanes, are produced. These enzymes are inhibited by non-steroidal anti-inflammatory drugs, including 
aspirin. If AA interacts with 5-lypoxigenase (5-LO), leukotrienes, also important mediators of inflammation, are produced. In the control of inflammatory response, the 
metabolite 15(S)-hydroxy-eicosatetraenoic acid (15S-HETE) is produced from LO from different cellular sources. This metabolite, through interaction with 5-LO in 
leukocytes by transcellular biosynthesis, produces some lipid mediators so-called lipoxins. Additionally, as an exclusive property of aspirin, by its reactive acetate 
group, aspirin can acetylate the active site of cyclooxygenase (COX)-2. This interaction inhibits its catalytic activity as a COX but redirects it, leading to the 
production of 15R-HETE from AA. 15R-HETE is then also converted through transcellular biosynthesis, by white-cell 5-LO, into aspirin-triggered lipoxins.
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p < 0.001) (3). However, other authors did not find differences 
in the beneficial effect of aspirin whether treatment was started 
before or after 16 weeks of gestation (38).
Regarding the risks of using LDA during pregnancy, most 
studies have found no association between its use and com-
plications in the mother or fetus, whether used in the first or 
third trimester. These studies show the lack of association of 
the use of such treatment with congenital anomalies, neonatal 
intraventricular hemorrhage, premature closure of the ductus 
arteriosus, maternal postpartum bleeding, or placental abrup-
tion (1, 39, 40). An adverse event such as vaginal bleeding 
not associated with gestational loss was described (41). Other 
maternal factors such as allergy or resistance to aspirin, in 
addition to gastric intolerance, could counterindicate the use 
of LDA in pregnancy (42).
Despite these controversial results, the preventive use of LDA 
in women at high risk for PE such as medical history of previ-
ous severe-PE, diabetes, chronic hypertension, renal disease, or 
autoimmune disease seems to be accepted (1, 39, 40). However, 
the controversy regarding the use of LDA persists in low-risk 
women. Currently, a panel of diagnostic tests exists to determine 
PE risk that includes uterine artery Doppler pulsatility index, and 
some placental biomarkers such as pregnancy-associated plasma 
protein A and placental growth factors (PLGF) (42). However, in 
developing countries, it is costly to have access to such tests and 
in that sense, it would be beneficial to recommend the use of LDA 
in women in whom PE risk is suspected.
USe OF ASPiRin in OBSTeTRiC APS
Antiphospholipid syndrome is an autoimmune disorder char-
acterized by the persistent presence of antiphospholipid (aPL) 
antibodies and clinical manifestations of vascular thrombosis or 
obstetrical complications, and also both aspects of the syndrome. 
Clinical criteria for obstetric APS include at least one of the 
following pathologies: early or late gestational loss, intrauterine 
growth restriction, placental insufficiency, or PE (43).
The mechanisms of injury of aPL involve activation of the 
endothelium, platelets, and monocytes, and complement activa-
tion and inhibition of anticoagulant proteins, leading to the 
phenomena of inflammation and thrombosis. It has been demon-
strated that aPL-associated obstetric complications are induced 
mainly by an inflammatory process and placental insufficiency 
rather than by thrombotic events at the maternal–fetal interface 
(44–49). aPL interferes with the migration, proliferation, and 
differentiation of trophoblast cells and decreases the production 
of placental human chorionic gonadotropin (hCG) (47, 50–58). 
Furthermore, aPL impairs interaction between the invading 
trophoblast and the endothelium of the uterine spiral arteries, 
which is a key process where spiral arteries are transformed 
into high-capacity low-resistance vessels to supply the growing 
nutritional demands of the fetus and the placenta (59).
Low doses of aspirin, alone or combined with low molecular 
heparin, is one of the preferred treatments in pregnant women 
with obstetric APS (4, 5, 60). Although a meta-analysis published 
in 2005 concluded that the combination of LDA plus unfrac-
tioned heparin had up to a 54% chance of reducing fetal loss (61), 
a subsequent randomized controlled-clinical trial did not find 
significant differences between the observed outcome for APS 
patients treated with aspirin alone in comparison with combined 
therapy of aspirin plus low molecular weight heparin (79.1 and 
77.8% of live births, respectively) (60). Because these protocols 
fail in about 20% of pregnant APS women, additional therapies 
have been proposed to add to conventional therapies (62, 63).
Low doses of aspirin reduced embryo resorption in a model 
of experimental APS induced in pregnant mice (64) and restored 
placental hCG secretion abolished by the effect of aPL (47). Over 
a period of 25 years, in our Reproduction Group of the University 
of Antioquia, LDA has been used alone or combined with other 
therapies to prevent recurrent spontaneous abortion. The other 
therapies include progesterone, heparin, folic acid, or lymphocyte 
immunotherapy. In a group of 111 women with a history of three 
or more abortions, who were treated with aspirin during their 
pregnancy, a coadjuvant effect of the treatment including aspirin 
was observed: if the patients who received some treatment were 
compared with patients non-treated at all, the odds ratio (OR) 
was 0.33 (0.13–0.81, p = 0.01); if the treatment including aspirin 
was compared with no treatment, the OR was 0.13 (0.04–0.43, 
p < 0.001) (65). Additionally, a prospective study of “single ther-
apy” with aspirin/heparin in patients with recurrent spontaneous 
abortion was carried out. These patients displayed autoimmune 
and alloimmune alterations, but lymphocyte immunotherapy 
was not administered to them; the gestational success in this 
group of patients was of 90.9% (10/11) versus 75.0% (6/8) in the 
concurrent group receiving both therapies (66). These results 
are empirical and lack the rigor of controlled-clinical trials, but 
encouraged us to continue exploring the use of LDA as a simple 
therapy in patients with recurrent pregnancy loss, associated or 
not with obstetric APS.
CLiniCAL AnD eXPeRiMenTAL  
eFFeCTS OF ATL
Aspirin-triggered lipoxin promotes the resolution of inflam-
mation and acts as antioxidant and immunomodulator. It also 
blocks the generation of reactive oxygen species in endothelial 
cells; it is a potent anti-inflammatory factor, inhibiting leuko-
cyte–endothelial interaction and cell chemiotaxis of neutrophils 
while promoting monocyte chemiotaxis and non-phlogistic 
phagocytosis of apoptotic neutrophils by macrophages; it inhib-
its NF-κB activation, and TNF-α secretion in activated T  cells 
(67–69). The effect of ATL has been used successfully in a wide 
range of murine disease models such as experimental asthma, 
trimellitic anhydride-induced delayed type of hypersensitivity 
reaction, chronic airway inflammation, and infection associated 
with cystic fibrosis. Additionally, ATL inhibits proliferation and 
angiogenesis in proliferative states such as chronic inflammation, 
ischemic diseases, and cancer (67, 70–72). These results open a 
range of potential therapeutic uses of ATL in a variety of inflam-
matory diseases.
Some authors have shown that the anti-inflammatory activity 
of aspirin is due to the production of nitric oxide (NO) and that 
this effect is mediated by the ATL-induced NO synthesis through 
constitutive and inducible NO synthases (eNOS and iNOS, 
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respectively) (25, 73). Meanwhile other authors argue that in the 
aspirin-mediated NO production the heme oxygenase-1 protein 
(HO-1) is involved, suggesting that more than one signaling 
pathway may be implicated. HO-1 is the inducible enzyme that 
catabolizes heme, leading to the generation of bilirubin, carbon 
monoxide, and iron. These molecules have antioxidant, antiapop-
totic, and cytoprotective properties (74, 75).
Although the usefulness of the ATL in the field of reproduction 
has not been studied extensively, some reports suggest the possi-
bilities for its use in this context. An increase of ALXR expression 
in the human endometrium during the menstrual cycle and in 
decidua during the first trimester of pregnancy was observed (76). 
In our group, we evaluated the effect of ATL on the inflammatory 
and oxidative response induced by plasma from preeclamptic 
women on endothelial cells (human umbilical venous endothelial 
cells). First, increased amounts of antiangiogenic factors (sFlt-1), 
pro-inflammatory (TNF) mediators, and products of lipid peroxi-
dation (TBARS and 8-isoprostane) in preeclamptic plasma were 
observed. Besides, leukocyte adhesion to endothelial cells was 
evaluated and both preeclamptic plasma and exogenous TBARS, 
and 8-isoprostane increased neutrophil adhesion to these cells, 
and this inflammatory response was reduced when neutrophils 
were incubated with ATL prior to coculture with endothelial 
cells (77). On the other hand, we assessed the modulatory 
effects of ATL over some aPL-altered trophoblast functions: the 
monoclonal anti-β2GPI antibodies ID2 and IIC5 significantly 
reduced spontaneous trophoblast cell migration and also dis-
rupted the trophoblast–endothelial cell interactions evaluated 
by a three-dimensional in vitro system of vascular remodeling. 
Both, migration and stability of the cocultures, were restored with 
simultaneous incubation with ATL. Similar results were obtained 
with serum samples from aPL-positive patients either with preg-
nancy morbidity alone (PM serum) or pregnancy morbidity plus 
vascular thrombosis (PM/VT) but ATL only restored aPL-altered 
trophoblast functions in the PM group, which could be an indi-
cation that the additional use of heparin is required in patients 
with PM/VT. An anti-inflammatory effect of ATL could not be 
demonstrated in these assays since ATL treatment did not resolve 
the aPL-induced pro-inflammatory and antiangiogenic responses 
of trophoblasts evaluated in terms of trophoblast secretion of the 
pro-inflammatory chemokine IL-8, the proangiogenic factor pla-
cental growth factor (PLGF) or the antiangiogenic factor soluble 
endoglin (59). As a whole, these findings the possibility of using 
ATL as an adjuvant therapy for women with PE or obstetric APS.
ASPiRin-inDUCeD LiPiD MeDiATORS 
DeRiveD FROM OMeGA-3 PUFAs: DO 
THeY HAve SOMe POTenTiAL USe in 
PReGnAnCY COMPLiCATiOnS?
Other lipid mediators derived from omega-3 PUFAs, eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), have been 
described more recently. EPA-derived mediators include resolvin 
E1 (RvE1) and RvE2; the DHA-derived mediators described 
are D-series resolvins, protectin D1, and maresins. Aspirin can 
induce the formation of RvE1 and the AT D-series resolvins, in 
a similar way to those of ATL (9). These mediators have potent 
pro-resolving inflammation activities (8). There are very few 
reports of the effect of endogenous lipid mediators or AT media-
tors derived from omega-3 PUFAs in pregnancy (78), but it has 
been reported that the dietary intake of these fatty acids increases 
resolvin and protectin levels in the rat placenta (79), and it has 
been proposed that omega-3 supplementation prevents preterm 
birth in humans (80).
Theoretically, the combination of omega-3 and LDA could 
have a synergistic effect in controlling inflammation. Some stud-
ies have found this effect in different scenarios: in TLR-7-activated 
microglia cells (81), in the treatment of three patients with progres-
sive IgA nephropathy (82), and in the decrease of atherosclerosis 
in apoE-null mice (83). On the other hand, other authors, in a 
group of healthy volunteers, did not find any effect of aspirin on 
the production of pro-resolving lipid mediators (84), nor that the 
presence of aspirin had any additional effect to that of the omega-3 
PUFA in decreasing markers of inflammation (85). The beneficial 
effect it could have by the combination of omega-3 PUFAs and 
LDA in preventing pregnancy complications such as PE, based on 
the production of AT-resolvins requires further studies.
COnCLUDinG ReMARKS
Aspirin, and particularly LDA, has a therapeutical potential beyond 
its already known effects in the prevention of several diseases 
such as myocardial infarction, strokes, atherothrombotic events, 
PE, and colon cancer. Besides the pharmacological effects that it 
shares with other NSAIDs, aspirin can induce other lipid-derived 
mediators with potent anti-inflammatory actions, and stimulation 
of the resolution of inflammation places aspirin in a privileged 
position in the therapeutic arsenal. In the context of prevention of 
some alterations of pregnancy, the prescription of drugs must be 
particularly careful to minimize the risk in both mother and fetus 
and even though aspirin is not exempt of risks, the risk–benefit 
balance is directed in favor of the beneficial effects. The use of 
LDA to prevent pregnancy complications such as PE and obstet-
ric APS has been based on the restauration of the prostacyclin/
thromboxane-A2 balance to the dominance of the former. This 
action is due to aspirin’s property to inhibit COX: platelets do not 
synthetize new protein, but endothelial cells do. However, in the 
light of newly identified mechanisms of action of aspirin, other 
immunomodulatory, anti-inflammatory, and antioxidant effects 
might be explored. The proposed challenge is a deep study of 
the molecular mechanisms implied in the effects of aspirin and 
of AT mediators to propose a more rational use of it based on 
the selection of patients who could benefit from aspirin, when the 
treatment should begin, and the dose that should be used.
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